更新于：2024-10-12
Ad26 Mos HIV trivalent vaccine(Janssen)
更新于：2024-10-12
概要
基本信息
在研机构- |
最高研发阶段无进展临床1/2期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
关联
4
项与 Ad26 Mos HIV trivalent vaccine(Janssen) 相关的临床试验A Combined Phase 1/2a, Exploratory Study of a Therapeutic Vaccine Using an Adenovirus Type 26 Vector Prime and Modified Vaccinia Ankara Boost Combination With Mosaic Inserts in HIV-1 Infected Adults Who Initiated Antiretroviral Treatment During Acute HIV Infection
The purpose of the study is to assess: 1 safety and tolerability of adenovirus serotype 26 (Ad26) prime and Modified Vaccinia Ankara (MVA) boost versus placebo in participants on suppressive antiretroviral therapy (ART) that was initiated during acute Human Immunodeficiency Virus (HIV) infection; 2) Measure the frequency and duration of sustained viremic control after receiving Ad26 prime/MVA boost or placebo, defined as greater than 24 weeks with plasma HIV ribonucleic acid (RNA) lesser than (<)50 copies/ml after antiretroviral (ARV) analytical treatment interruption (ATI).
开始日期2016-09-01 |
A Randomized, Parallel-Group, Placebo-Controlled, Double-Blind Phase 1/2a Study in Healthy HIV Uninfected Adults to Assess the Safety/Tolerability and Immunogenicity of 2 Different Prime/Boost Regimens; Priming With Trivalent Ad26.Mos.HIV and Boosting With Trivalent Ad26.Mos.HIV And Clade C Gp140 Plus Adjuvant or Priming With Tetravalent Ad26.Mos4.HIV and Boosting With Tetravalent Ad26.Mos4.HIV and Clade C Gp140 Plus Adjuvant
The purpose of this study is to assess the safety/tolerability of the 2 different vaccine regimens of priming with trivalent Ad26.Mos.HIV and boosting with trivalent Ad26.Mos.HIV and Clade C gp140 plus adjuvant or priming with tetravalent Ad26.Mos4.HIV and boosting with Ad26.Mos4.HIV and Clade C glycoprotein (gp)140 plus adjuvant. Immune responses of the different vaccine schedules will be assessed.
开始日期2016-07-08 |
A Randomized, Parallel-group, Placebo-controlled, Double-blind Phase 1 Study in Healthy HIV-uninfected Adults to Evaluate Safety/Tolerability and Immunogenicity of Different Vaccine Schedules With Ad26.Mos.HIV and Clade C gp140
The primary purpose of this study is to assess safety, tolerability of the different vaccine schedules (different regimen durations and different number of dose administrations) with Ad26.Mos.HIV and Clade C Glycoprotein (gp) 140 and to assess Envelope (Env)-binding Antibody (Ab) responses of the different vaccine schedules.
开始日期2016-03-28 |
100 项与 Ad26 Mos HIV trivalent vaccine(Janssen) 相关的临床结果
登录后查看更多信息
100 项与 Ad26 Mos HIV trivalent vaccine(Janssen) 相关的转化医学
登录后查看更多信息
100 项与 Ad26 Mos HIV trivalent vaccine(Janssen) 相关的专利（医药）
登录后查看更多信息
5
项与 Ad26 Mos HIV trivalent vaccine(Janssen) 相关的文献（医药）2021-04-27·Applied and environmental microbiology
The Nutritional Significance of Intestinal Fungi: Alteration of Dietary Carbohydrate Composition Triggers Colonic Fungal Community Shifts in a Pig Model
Article
作者: Wu, Aimin ; Li, Hua ; He, Jun ; Li, Jiayan ; Huang, Zhiqing ; Yu, Jie ; Yu, Bing ; Zhou, Hua ; Yan, Hui ; Wang, Huifen ; Wang, Quyuan ; Luo, Yuheng ; Chen, Daiwen ; Zheng, Ping ; Mao, Xiangbing
Although fungi are a large group of microorganisms along with bacteria and archaea in the gut of monogastric animals, the nutritional significance of fungi has been ignored for a long time. Our previous studies revealed a distinct fungal community in the gut of grazing Tibetan pigs (
1
) and a close correlation between fungal species and short-chain fatty acids, the main microbial metabolites of carbohydrates in the hindgut of pigs (
2
).
2020-10-01·The lancet. HIV1区 · 医学
Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study
1区 · 医学
Article
作者: Johannes P Langedijk ; Steven Nijs ; M Juliana McElrath ; Frank Wegmann ; Ken Mayer ; Colleen Kelly ; Michael Keefer ; Etienne Karita ; Philipp Mann ; Joseph Nkolola ; Hong Van Tieu ; Zelda Euler ; Maria G Pau ; Susan Buchbinder ; Stephen R Walsh ; Katleen Callewaert ; James G Kublin ; Guido Ferrari ; Karen Buleza ; Magda Sobieszczyk ; Georgia D Tomaras ; Lauren Peter ; David Montefiori ; Merlin L. Robb ; Frank Tomaka ; Kristen W. Cohen ; Michal Sarnecki ; Srilatha Edupuganti ; Daniel J Stieh ; Lorenz Scheppler ; Dan H Barouch ; Nadine Rouphael ; Dimitri Goedhart ; Trevor A. Crowell ; Hanneke Schuitemaker ; Lawrence Corey ; Galit Alter ; Ian Frank ; Lindsey R Baden ; Julie A. Ake ; Paul Goepfert
BACKGROUND:
Bioinformatically designed mosaic antigens increase the breadth of HIV vaccine-elicited immunity. This study compared the safety, tolerability, and immunogenicity of a newly developed, tetravalent Ad26 vaccine with the previously tested trivalent formulation.
METHODS:
This randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study (TRAVERSE) was done at 11 centres in the USA and one centre in Rwanda. Eligible participants were adults aged 18 to 50 years, who were HIV-uninfected, healthy at screening based on their medical history and a physical examination including laboratory assessment and vital sign measurements, and at low risk of HIV infection in the opinion of study staff, who applied a uniform definition of low-risk guidelines that was aligned across sites. Enrolled participants were randomly assigned at a 2:1 ratio to tetravalent and trivalent groups. Participants in tetravalent and trivalent groups were then further randomly assigned at a 5:1 ratio to adenovirus 26 (Ad26)-vectored vaccine and placebo subgroups. Randomisation was stratified by region (USA and Rwanda) and based on a computer-generated schedule using randomly permuted blocks prepared under the sponsor's supervision. We masked participants and investigators to treatment allocation throughout the study. On day 0, participants received a first injection of tetravalent vaccine (Ad26.Mos4.HIV or placebo) or trivalent vaccine (Ad26.Mos.HIV or placebo), and those injections were repeated 12 weeks later. At week 24, vaccine groups received a third dose of tetravalent or trivalent together with clade C gp140, and this was repeated at week 48, with placebos again administered to the placebo group. All study vaccines and placebo were administered by intramuscular injection in the deltoid muscle. We assessed adverse events in all participants who received at least one study injection (full analysis set) and Env-specific binding antibodies in all participants who received at least the first three vaccinations according to the protocol-specified vaccination schedule, had at least one measured post-dose blood sample collected, and were not diagnosed with HIV during the study (per-protocol set). This study is registered with Clinicaltrials.gov, NCT02788045.
FINDINGS:
Of 201 participants who were enrolled and randomly assigned, 198 received the first vaccination: 110 were in the tetravalent group, 55 in the trivalent group, and 33 in the placebo group. Overall, 185 (93%) completed two scheduled vaccinations per protocol, 180 (91%) completed three, and 164 (83%) completed four. Solicited, self-limiting local, systemic reactogenicity and unsolicited adverse events were similar in vaccine groups and higher than in placebo groups. All participants in the per-protocol set developed clade C Env binding antibodies after the second vaccination, with higher total IgG titres after the tetravalent vaccine than after the trivalent vaccine (10 413 EU/mL, 95% CI 7284-14 886 in the tetravalent group compared with 5494 EU/mL, 3759-8029 in the trivalent group). Titres further increased after the third and fourth vaccinations, persisting at least through week 72. Other immune responses were also higher with the tetravalent vaccine, including the magnitude and breadth of binding antibodies against a cross-clade panel of Env antigens, and the magnitude of IFNγ ELISPOT responses (median 521 SFU/106 peripheral blood mononuclear cells [PBMCs] in the tetravalent group and median 282 SFU/106 PBMCs in the trivalent group after the fourth vaccination) and Env-specific CD4+ T-cell response rates after the third and fourth vaccinations. No interference by pre-existing Ad26 immunity was identified.
INTERPRETATION:
The tetravalent vaccine regimen was generally safe, well-tolerated, and found to elicit higher immune responses than the trivalent regimen. Regimens that use this tetravalent vaccine component are being advanced into field trials to assess efficacy against HIV-1 infection.
FUNDING:
National Institutes of Health, Henry M Jackson Foundation for Advancement of Military Medicine and the US Department of Defense, Ragon Institute of MGH, MIT, & Harvard, Bill & Melinda Gates Foundation, and Janssen Vaccines & Prevention.
2018-07-01·Lancet (London, England)1区 · 医学
Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)
1区 · 医学
Article
作者: Chinyenze, Kundai ; Swann, Edith ; Tomaka, Frank L ; Vreugdenhil, Jessica ; Zahn, Roland ; Chandrashekar, Abishek ; Garrett, Nigel ; Nitayapan, Sorachai ; Gray, Glenda ; Alter, Galit ; Baden, Lindsey ; Sadoff, Jerald ; Euler, Zelda ; Callewaert, Katleen ; Li, Wenjun ; Tomaras, Georgia D ; Karita, Etienne ; Feldman, Robert ; Lazarus, Erica ; Lucksinger, Gregg ; Hutter, Julia ; Michael, Nelson L ; Schuitemaker, Hanneke ; Feddes-de Boer, Karin ; Lavreys, Ludo ; McElrath, M Juliana ; Scheppler, Lorenz ; Mpendo, Juliet ; Kibuuka, Hannah ; Peter, Lauren ; Pau, Maria G ; Jetton, David ; Stieh, Daniel J ; van Manen, Daniëlle ; Borremans, Caroline ; Bart, Stephan ; Nkolola, Joseph P ; Johnson, Jennifer ; Korber, Bette ; Laher, Fatima ; Nijs, Steven ; Barouch, Dan H ; Weijtens, Mo ; Hendriks, Jenny ; Priddy, Frances ; Wegmann, Frank ; Pitisuttithum, Punnee ; Robb, Merlin L ; Stephenson, Kathryn E ; Tolboom, Jeroen ; Borducchi, Erica N ; Montefiori, David C ; Campbell, Thomas ; Roten, Raphaele ; Mngadi, Kathy ; Frahm, Nicole
BACKGROUND:
More than 1·8 million new cases of HIV-1 infection were diagnosed worldwide in 2016. No licensed prophylactic HIV-1 vaccine exists. A major limitation to date has been the lack of direct comparability between clinical trials and preclinical studies. We aimed to evaluate mosaic adenovirus serotype 26 (Ad26)-based HIV-1 vaccine candidates in parallel studies in humans and rhesus monkeys to define the optimal vaccine regimen to advance into clinical efficacy trials.
METHODS:
We conducted a multicentre, randomised, double-blind, placebo-controlled phase 1/2a trial (APPROACH). Participants were recruited from 12 clinics in east Africa, South Africa, Thailand, and the USA. We included healthy, HIV-1-uninfected participants (aged 18-50 years) who were considered at low risk for HIV-1 infection. We randomly assigned participants to one of eight study groups, stratified by region. Participants and investigators were blinded to the treatment allocation throughout the study. We primed participants at weeks 0 and 12 with Ad26.Mos.HIV (5 × 1010 viral particles per 0·5 mL) expressing mosaic HIV-1 envelope (Env)/Gag/Pol antigens and gave boosters at weeks 24 and 48 with Ad26.Mos.HIV or modified vaccinia Ankara (MVA; 108 plaque-forming units per 0·5 mL) vectors with or without high-dose (250 μg) or low-dose (50 μg) aluminium adjuvanted clade C Env gp140 protein. Those in the control group received 0·9% saline. All study interventions were administered intramuscularly. Primary endpoints were safety and tolerability of the vaccine regimens and Env-specific binding antibody responses at week 28. Safety and immunogenicity were also assessed at week 52. All participants who received at least one vaccine dose or placebo were included in the safety analysis; immunogenicity was analysed using the per-protocol population. We also did a parallel study in rhesus monkeys (NHP 13-19) to assess the immunogenicity and protective efficacy of these vaccine regimens against a series of six repetitive, heterologous, intrarectal challenges with a rhesus peripheral blood mononuclear cell-derived challenge stock of simian-human immunodeficiency virus (SHIV-SF162P3). The APPROACH trial is registered with ClinicalTrials.gov, number NCT02315703.
FINDINGS:
Between Feb 24, 2015, and Oct 16, 2015, we randomly assigned 393 participants to receive at least one dose of study vaccine or placebo in the APPROACH trial. All vaccine regimens demonstrated favourable safety and tolerability. The most commonly reported solicited local adverse event was mild-to-moderate pain at the injection site (varying from 69% to 88% between the different active groups vs 49% in the placebo group). Five (1%) of 393 participants reported at least one grade 3 adverse event considered related to the vaccines: abdominal pain and diarrhoea (in the same participant), increased aspartate aminotransferase, postural dizziness, back pain, and malaise. The mosaic Ad26/Ad26 plus high-dose gp140 boost vaccine was the most immunogenic in humans; it elicited Env-specific binding antibody responses (100%) and antibody-dependent cellular phagocytosis responses (80%) at week 52, and T-cell responses at week 50 (83%). We also randomly assigned 72 rhesus monkeys to receive one of five different vaccine regimens or placebo in the NHP 13-19 study. Ad26/Ad26 plus gp140 boost induced similar magnitude, durability, and phenotype of immune responses in rhesus monkeys as compared with humans and afforded 67% protection against acquisition of SHIV-SF162P3 infection (two-sided Fisher's exact test p=0·007). Env-specific ELISA and enzyme-linked immunospot assay responses were the principal immune correlates of protection against SHIV challenge in monkeys.
INTERPRETATION:
The mosaic Ad26/Ad26 plus gp140 HIV-1 vaccine induced comparable and robust immune responses in humans and rhesus monkeys, and it provided significant protection against repetitive heterologous SHIV challenges in rhesus monkeys. This vaccine concept is currently being evaluated in a phase 2b clinical efficacy study in sub-Saharan Africa (NCT03060629).
FUNDING:
Janssen Vaccines & Prevention BV, National Institutes of Health, Ragon Institute of MGH, MIT and Harvard, Henry M Jackson Foundation for the Advancement of Military Medicine, US Department of Defense, and International AIDS Vaccine Initiative.
2
项与 Ad26 Mos HIV trivalent vaccine(Janssen) 相关的新闻（医药）2023-08-05
进入7月以来，各大跨国药企陆续发布了2023年Q2财报以及H1财报。详看2023年上半年MNC成绩单：全球制药TOP3洗牌，强生一马当先；全球药王之争落幕，默沙东K药超越修美乐正式成为新晋“药王”；默沙东、阿斯利康、罗氏中国区业绩亮眼，各大药企瘦身、调整研发项目频繁......01全球制药TOP3洗牌，辉瑞跌至第三据初步统计，截至目前，已有超10家MNC公布了2023年Q2财报和中报。今年上半年，强生以总营收502.76亿美元强势拿下第一，相较去年同比上涨了6%，罗氏发挥基本稳定居第二。 同比增速来看，仅有强生、诺华、阿斯利康、赛诺菲、GSK呈正增长；罗氏、辉瑞、默沙东、艾伯维、BMS、渤健增速放缓。注：罗氏2023H1营收297.79亿瑞士法郎（约348亿美元，按最新汇率1 瑞士法郎 ≈ 1.1684 美元计算)从制药业务上来看，强生上半年收入271.44亿美元，产品主要集中在免疫、肿瘤、神经、抗感染、肺动脉高压以及心血管&代谢治疗领域。其中，免疫和肿瘤是强生的主要业绩来源，今年上半年分别贡献了86.08亿美元和85.10亿美元。在制药领域，今年下半年强生将迎来多项关键里程碑，如GPRC5D/CD3双抗talquetamab的欧美监管批准和高血压药物aprocitentan的美国监管批准等。罗氏制药板块营收226.81亿瑞士法郎，肿瘤领域依旧是其主要阵地，贡献了97.75亿瑞士法郎的收入，增长4%；其它领域里神经科学、血友病A、眼科、感染性疾病业务收入均实现两位数增长。除去COVID-19的影响，罗氏预计制药业务和诊断业务的销售额都将实现稳健增长。具体产品里，奥瑞珠单抗、艾美赛珠单抗、利司扑兰、Phesgo、奥司他韦等均保持强势增长；眼科产品VEGF-A/Ang2双抗Vabysmo增速迅猛，上半年销售收入达9.57亿瑞士法郎（10.5亿美元），增速较快；受生物类似药、竞品等冲击，罗氏肿瘤学“三驾马车”贝伐珠单抗、曲妥珠单抗、利妥昔单抗收入继续下滑。今年上半年，辉瑞新冠mRNA疫苗、新冠口服药Paxlovid销售额分别为45.52亿美元、42.12亿美元。另一边，其抗凝血药物Eliquis（36.36亿美元），肺炎结合疫苗（29.81亿美元），CDK4/6抑制剂Ibrance（23.91亿美元），以及3款罕见心肌病药物Vyndaqel、Vyndamax、Vynmac等产品表现亮眼。值得一提的是，2023年Q1辉瑞以428亿美元的价格收购了ADC研发龙头Seagen，为寻找新的业绩增长点助力......02药王易主，K药超越修美乐着MNC半年报公布，各家2023H1销冠产品收入也一并揭晓。其中，默沙东Keytruda帕博利珠单抗以120.65亿美元销售额拿下全球“药王”宝座，昔日“药王”修美乐75.53亿美元营收紧随其后。K药、修美乐多年的“药王”之争落下帷幕。值得关注的是，赛诺菲的核心产品Dupixent上半年销售额48.78亿欧元，合53.5亿美元，预计今年将首次超过100亿美元大关；强生的Stelara（乌司奴单抗）上半年收入52.41亿美元（+7.2%），业界分析称该药有望在年底挤进百亿美元俱乐部。百时美施贵宝的O药2022年总营收为82.49亿美元，结合今年上半年的表现，O药在2023年总营收有望超越去年。Entresto已晋升为诺华最畅销药物，所有地区都实现了强劲的两位数增幅，半年销售总额达到29.15亿美元；Tagrisso（奥希替尼）是阿斯利康当前最畅销的产品，2023上半年收入29.15亿美元，增长12%。奥希替尼辅助治疗NSCLC的III期ADAURA研究数据极大促进了该产品的需求增长，不过受到医保降价影响，整体业绩增长趋缓。GSK带状疱疹疫苗Shingrix继续保持强劲增势：2023年上半年营收17.13亿英镑，接近2021年年销售额。据悉，Shingrix强劲的销售表现主要得益于其在全球范围内的扩张和需求的增长。03多家MNC中国区业绩亮眼，瘦身、砍项目频繁2023年上半年，多家MNC中国区业绩亮眼：罗氏披露的制药业务和诊断业务营收里，中国区收入合计为30.8亿美元。其中，制药业务收入226.81亿瑞士法郎，中国区业务收入15.05亿瑞士法郎（+3%）；诊断业务收入70.98亿瑞士法郎，中国区收入12.89亿瑞士法郎（+10%）。 据介绍，中国区制药业务主要驱动因素包括抗流感药达菲、乳腺癌药物帕捷特、流感药物速福达、新冠肺炎和关节炎药物雅美罗，以及用于淋巴瘤的抗体偶联药物（ADC）优罗华。 阿斯利康中国区业务一直排在前列，今年上半年阿斯利康中国区收入30.43亿美元，同比增长7%，贡献了新兴市场里近一半的业绩。其备受关注的明星产品Enhertu（德曲妥珠单抗），上半年带来了5.8亿美元的收入。该药物今年在中国获批HER2阳性乳腺癌适应症，并且用于低表达乳腺癌新适应症也已于7月获批。 默沙东中国区业绩也十分亮眼，其制药业务收入261.79亿美元，中国区收入35.81亿美元，同比增长13.7%。其中，值得关注的是2022年8月，Gardasil 9在中国扩龄至9-45岁女性，促使其销售额实现强劲增长。默沙东预计，2023年Gardasil/Gardasil 9的销售额将突破2022年的数据（68.97亿美元）。 同样引人关注的是，2023年上半年MNC瘦身动作频繁。削减、终止研发项目不断，强生削减了乙肝（JNJ-3989、JNJ-7744、JNJ-3283）、丁肝（JNJ-3989）、流感（JNJ-0953）和HIV（VAC89220、一款处于临床I期的超长效HIV药物）管线。 罗氏中报提到，将终止几款候选药物开发，包括处于III期阶段的替奈普酶治疗卒中适应症，II期阶段血友病A基因疗法RG6358，以及4款尚处于I期研究阶段的新分子实体药物。 为聚焦核心领域发展，诺华延续了2022年的“瘦身”战略，不仅终止NASH疗法PLN-1474、镰状细胞病（SCD）药物OTQ923/HIX763的开发合作项目，还以25亿美元总交易额剥离了干眼病资产给Bausch+Lomb。 渤健广泛调整管线，终止了多个临床开发项目，包括LRRK2抑制剂BIIB122治疗帕金森病的III期临床。渤健研发管线优先级调整已基本完成，能够更加专注于具有高潜力的项目。 资料参考：MNC财报、医药观澜、药时空等公开资料免责声明：“药渡Daily”公众号所转载文章来源于其他公众号平台，主要目的在于分享行业相关知识，传递当前最新资讯。图片、文章版权均属于原作者所有，如有侵权，请及时告知，我们会在24小时内删除相关信息。END👇关注药渡数据媒体矩阵
财报并购疫苗生物类似药抗体药物偶联物
2023-07-22
·药融圈
▲8月03-04日 CMC-China大会 · 限时免费扫码报名中注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需得到授权。7月20日，强生(Johnson & Johnson)公布第二季度财报，根据财报显示，公司Q2总营收255.3亿美元，同比增长6.3%。目前预计全年的总体销售额区间为988亿美元至998亿美元，区间较4月时的预期高出约10亿美元。 Q2药品销售额为137.3亿美元，同比增长超过3%（不包括新冠疫苗的销售额，该制药部门的销售额为134.5亿美元）。这一增长趋势受到Darzalex(达雷妥尤单抗，一种治疗多发性骨髓瘤的生物制剂)、Erleada(一种治疗前列腺癌的药物)和Stelara(一种用于治疗多种免疫介导的炎症性疾病的重磅药物)销售额的大力推动。今年晚些时候，强生将失去对Stelara的专利保护。具体到各药品，其中达雷妥尤单抗 涨势迅猛，保持超 20% 增速，今年有望逼近百亿美元年销售额；与传奇生物合作的 CAR-T 疗法 西达基奥仑赛（CARVYKTI）收入增长可观，去年全年卖了 1.34 亿美元， Q2 单季度销售就过亿。同比涨幅超 30% 的产品还包括 ERLEADA、CONCERTA、SPRAVATO。不过，制药业务销售额增长的一部分被关节炎药物Remicade的销售额下降所抵消，Remicade面临着生物仿制药的竞争——一种结构几乎相同的低成本药物。截止发稿前，强生股票涨6.1%，创2022年2月以来最大盘中涨幅，报168.4美元，目前市值4376亿美元。除了医疗科技以及医疗保健技术，强生还专注于开发针对不同疾病领域的药物。根据财报，在研发管线方面，强生也做出了优化调整。其正在开发的药物不再包括乙肝（JNJ-3989、JNJ-7744、JNJ-3283）、丁肝 （JNJ-3989）、流感（JNJ-0953）和HIV（VAC89220、一款处于临床I期的超长效HIV药物）管线。自今年第一季度以来，强生已从其传染病项目中剔除了7个项目，其中大多数是乙型肝炎疗法，作为其研发业务的“优先级”的一部分。此前，强生一直在2期试验中测试JNJ-3989，这是一种针对乙型肝炎以及乙型和D型肝炎合并感染的联合疗法。JNJ-7744和JNJ-3283治疗乙型肝炎均处于I期，而JNJ-0953治疗流感处于II期。 去年5月9日，强生宣布，旗下杨森终止与Bavarian Nordic公司的合作和许可协议。该协议的主要内容是：利用Bavarian Nordic公司的MVA-BN技术，开发针对乙型肝炎病毒和人类乳头瘤病毒的潜在疫苗。截止合作终止前，强生未使用该技术开发乙肝疫苗。参考资料：药融云数据库强生财报www.jnj.com版权声明：本文转自生物药大时代，如不希望被转载的媒体或个人可与我们联系，我们将立即删除关于CMC-China 博览会融合产业力量，重构行业未来！本次CMC-China博览会汇聚300+医药及上下游全产业链的企业积极报名参展，数千名专业观众报名参观，展会现场将举办15场专业论坛。充分体现了“医药人办医药展，专业人办专业展”的理念。了解更多：一文看最全议程！8月3-4日：2023第五届中国国际生物&化学制药博览会点分享点点赞点在看
财报免疫疗法疫苗细胞疗法临床1期
100 项与 Ad26 Mos HIV trivalent vaccine(Janssen) 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| HIV感染 | 临床2期 | 美国 | 2014-12-22 | |
| HIV感染 | 临床2期 | 卢旺达 | 2014-12-22 | |
| HIV感染 | 临床2期 | 南非 | 2014-12-22 | |
| HIV感染 | 临床2期 | 泰国 | 2014-12-22 | |
| HIV感染 | 临床2期 | 乌干达 | 2014-12-22 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床1/2期 | - | 201 | (Tetravalent Ad26.Mos4.HIV Vaccine) | 製窪糧鬱艱醖鏇遞鏇鹹(廠選簾顧鬱選壓壓衊糧) = 遞膚鹹餘遞齋繭網蓋醖 遞選壓鏇淵齋壓齋艱簾 (憲夢遞衊醖製選範觸獵, 鏇鹽願糧夢糧鑰衊窪齋 ~ 憲觸鑰衊鹽選顧範憲憲) 更多 | - | 2023-06-09 | |
Ad26.Mos.HIV Vaccine (Trivalent Ad26.Mos.HIV Vaccine) | 製窪糧鬱艱醖鏇遞鏇鹹(廠選簾顧鬱選壓壓衊糧) = 糧範淵餘糧廠範繭範鬱 遞選壓鏇淵齋壓齋艱簾 (憲夢遞衊醖製選範觸獵, 膚繭範醖鬱願衊觸衊廠 ~ 鑰獵網醖糧鬱齋淵繭遞) 更多 | ||||||
临床1/2期 | 27 | MVA-Mosaic+Ad26.Mos.HIV (Ad26.Mos.HIV Vaccine or MVA Mosaic Vaccine) | 鬱網鏇觸觸遞願衊顧蓋(廠淵簾築獵製選獵範選) = 鹽鏇範顧鑰範醖鹹憲築 鹽夢鹹壓遞鬱窪窪淵鏇 (膚廠鏇廠鬱簾繭襯蓋壓, 鏇簾範蓋憲鑰齋夢觸鬱 ~ 簾淵願築觸構觸廠蓋觸) 更多 | - | 2022-03-11 | ||
Placebo (Placebo) | 鬱網鏇觸觸遞願衊顧蓋(廠淵簾築獵製選獵範選) = 膚蓋膚艱鹽淵築網餘壓 鹽夢鹹壓遞鬱窪窪淵鏇 (膚廠鏇廠鬱簾繭襯蓋壓, 願積簾繭襯鹹餘範積夢 ~ 構觸壓繭積鬱窪積積憲) 更多 | ||||||
临床1/2期 | 393 | Ad26+gp140 (Group 1: Ad26/Ad26 + gp140 High Dose (HD)) | 齋憲餘網願遞鑰構膚範(鏇醖獵簾鑰窪簾鹽衊遞) = 遞鏇窪觸構鏇蓋積繭築 願鹹襯醖衊鏇壓膚觸鬱 (築鹹憲壓淵齋選艱選願, 蓋觸範齋觸鹽觸衊艱繭 ~ 選觸淵獵鬱選窪膚製窪) 更多 | - | 2020-11-04 | ||
Ad26+gp140 (Group 2: Ad26/Ad26 + gp140 Low Dose (LD)) | 齋憲餘網願遞鑰構膚範(鏇醖獵簾鑰窪簾鹽衊遞) = 壓憲蓋願鑰繭觸製窪鑰 願鹹襯醖衊鏇壓膚觸鬱 (築鹹憲壓淵齋選艱選願, 網製築糧憲衊壓選鹹繭 ~ 積選廠餘鹹醖繭築淵遞) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
标准版
¥16800
元/账号/年
新药情报库 ｜ 省钱又好用！
立即使用
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用